Volume Replacement With Albumin in Severe Sepsis (ALBIOS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00707122|
Recruitment Status : Completed
First Posted : June 30, 2008
Last Update Posted : November 10, 2015
BACKGROUND The association between mortality and hypoalbuminemia has been observed in several diseases. Nonetheless, the efficacy of albumin on survival in critically ill patients is controversial. Several meta-analyses have reported either negative, neutral, or beneficial effects of albumin administration. To clarify this controversy, a large multicenter prospective study has been performed, comparing the effects of 4% albumin vs. saline for volume replacement in critically ill patients. Although no difference in the overall mortality has been observed, a predefined subgroup analysis has shown a trend of longer survival in septic patients treated with albumin. As fluid replacement has been shown to be critical in sepsis, and based on both its primary (oncotic) and secondary properties (anti-inflammatory), it is conceivable that the use of albumin for volume replacement and for treating hypoalbuminemia may have a beneficial effects on survival of septic patients.
OBJECTIVES Primary objective: to verify whether volume replacement with albumin (treated group) and its maintenance within plasmatic physiologic range (equal or above 30 g/l) improves survival of patients with severe sepsis of septic shock, as compared to crystalloids (control group). Secondary objectives: to verify the differences in organ dysfunctions, hospital and intensive care unit (ICU) length of stay between the treated and control group.
METHODS About 1350 patients with severe sepsis or septic shock will be randomized to receive either albumin or crystalloids as fluid therapy. Volume replacement will be performed for both groups according to the early-goal directed therapy. Treated group will receive 60 gr albumin infusion after randomization, and 40-60 gr albumin daily infusion to maintain serum album level equal or above 30 g/l. Control group will receive crystalloids for the entire study; albumin administration will be allowed only when daily serum albumin level will be lower than 15 g/l. Patients will be treated until the 28th day after randomization or until ICU discharge, whichever comes first.
EXPECTED RESULTS Primary outcomes: absolute risk reduction of overall mortality of 7.5% at 28th day, with a further control at 90th day, following randomization. Secondary outcomes: reduction of number and severity of organ dysfunctions (as assessed by the Sequential Organ Failure Assessment score), reduction of ICU and hospital length of stay.
|Condition or disease||Intervention/treatment||Phase|
|Severe Sepsis Septic Shock||Other: Albumin and Crystalloids Other: Crystalloids||Phase 3|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1818 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy of Albumin Administration for Volume Replacement in Patients With Severe Sepsis or Septic Shock - the ALBumin Italian Outcome Sepsis (ALBIOS) Study|
|Study Start Date :||July 2008|
|Primary Completion Date :||April 2013|
|Study Completion Date :||October 2013|
1, Albumin and Crystalloids
Other: Albumin and Crystalloids
From day 2 to day 28 (or until ICU discharge, whichever comes first), fluid will be administered as follows:
1. treated group: albumin will be infused on a daily basis, aimed to maintain its serum concentration equal or above 30 g/l (8). In particular, after the daily determination of its serum level:
Volume replacement will be performed in both the treated and the control group according to the "early-goal directed therapy".
control group: crystalloids infusion will be allowed whenever necessary on a clinical basis. Albumin administration will be restricted to emergency use, as clinically judged and documented according to the standard criteria of each participating unit. No other colloids will be allowed.
- mortality rate at the 28th day after randomization, with a further control at 90th day. [ Time Frame: mortality at 28th and 90th day after randomization ]
- Number and severity of organ dysfunction (as recorded by the SOFA score) [ Time Frame: At 28th day after randomization and at ICU discharge ]
- ICU length of stay [ Time Frame: ICU discharge ]
- Hospital length of stay [ Time Frame: Hospital discharge ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00707122
|Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico; Via F. Sforza 35|
|Milano, Italy, 20135|
|Principal Investigator:||Luciano Gattinoni, MD||Dipartimento di Anestesiologia, Terapia Intensiva e Scienze Dermatologiche; Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico|
|Study Chair:||Pietro Caironi, MD||Dipartimento di Anestesiologia, Terapia Intensiva e Scienze Dermatologiche; Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico|
|Study Chair:||Antonio Pesenti, MD||Dipartimento di Medicina Perioperatoria e Terapia Intensiva, Azienda Ospedaliera San Gerardo di Monza, Università degli Studi Milano-Bicocca|
|Study Chair:||Roberto Fumagalli, MD||Dipartimento di Medicina Perioperatoria e Terapia Intensiva, Azienda Ospedaliera San Gerardo di Monza, Università degli Studi Milano-Bicocca|
|Study Chair:||Gianni Tognoni, MD||Consorzio Mario Negri Sud, S. Maria Imbaro|
|Study Chair:||Marilena Romero||Consorzio Mario Negri Sud, S. Maria Imbaro|
|Study Chair:||Roberto Latini, MD||Istituto Di Ricerche Farmacologiche Mario Negri|
|Study Chair:||Serge Masson||Istituto Di Ricerche Farmacologiche Mario Negri|